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Abstract: 
Background/Aims: Epithelial–to-mesenchymal cell transformation (EMT) is the 
trans-differentiation of tubular epithelial cells into myofibroblasts, an event underlying 
progressive chronic kidney disease in diabetes, resulting in fibrosis. Mainly reported in 
proximal regions of the kidney, EMT is now recognized as a key contributor to the loss of 
renal function throughout the nephron in diabetic nephropathy (DN). Concomitant up-
regulation of TGF-β in diabetes makes this pro-fibrotic cytokine an obvious candidate in the 
development of these fibrotic complications. This article reviews recent findings clarifying 
our understanding of the role of TGF-β and associated sub-cellular proteins in EMT. 
Methods: To understand the pathology of EMT and the role of TGF-β, we reviewed the 
literature using Pubmed for English Language articles that contained key words related to 
EMT, TGF- and DN. Results: EMT and phenotypic plasticity of epithelial cells throughout 
the nephron involves cytoskeletal reorganization and de novo acquisition of classic 
mesenchymal markers. Concurrent down-regulation of epithelial adhesion molecules results 
in a loss of function and decreased cell coupling, contributing to a loss of epithelial integrity. 
TGF-1 is pivotal in mediating these phenotypic changes. Conclusion: TGF-β induced EMT 
is a key contributor to fibrotic scar formation as seen in DN and novel routes for future 
therapeutic intervention are discussed.  
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Introduction:   
Diabetic nephropathy (DN) is the single commonest cause of entry into the renal replacement 
therapy programme and the leading cause of end-stage renal failure in diabetes mellitus [1]. 
DN refers to a set of structural and functional changes which arise in response to chronic 
glycaemic assault [2]. Structural abnormalities include; hypertrophy, glomerular basement 
membrane thickening, tubular atrophy and interstitial fibrosis [3]. These changes contribute to 
increased glomerular filtration rate, proteinuria, systemic hypertension and loss of renal 
function [3]. Histologically, DN is characterised by an accumulation of extracellular matrix 
(ECM) proteins in both the glomerular mesangium and tubular interstitum culminating in a 
decline in excretory function and excessive renal scarring [3][4]. Renal fibrosis manifests 
itself as glomeruosclerosis, tubulinterstitial fibrosis, infiltration of inflammatory mediators 
and the activation of alpha-smooth muscle actin (-SMA)-positive myofibroblasts. Tubular 
epithelial to mesenchymal transition (EMT), or the transdifferentiation of tubular epithelial 
cells into myofibroblasts, mediates excessive deposition of the ECM. This ability to switch 
phenotype stems from a unique plasticity of epithelial cells and is implicated in the generation 
of interstital fibroblasts in the diseased kidney. EMT of proximal tubule cells (PTC) has been 
clearly documented in DN and overwhelming evidence implicates Transforming Growth 
Factor-beta 1 (TGF-1) as the predominant agent mediating these fibrotic changes. This 
review discusses our current knowledge of TGF-1 induced EMT in DN in both the PTC and 
collecting duct of the kidney. Finally, we discuss potential therapeutic strategies to inhibit 
renal fibrogenesis in diabetes.  
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Epithelial-to-mesenchymal-transition in the kidney:  
Developmentally, renal tubules are derived from the metanephric mesenchyme through a 
process termed mesenchymal-to-epithelial transdifferentiation (MET). This cellular 
differentiation is not static and cells retain the ability to revert back to their original 
mesenchymal phenotype through EMT. Commonly associated with epithelia of embryonic 
origin, this plasticity is critical in early stages of development. In adults, EMT is associated 
with tissue injury and repair; a process instigated as the demand for fibroblasts and wound 
healing increases [5]. 
 
In EMT, the loss of epitheial characteristics coincides with the acquisition of proteins 
associated with a mesenchymal phenoptye. These morphological and phenotypic changes 
occur at four different stages: (i) the loss of epithelial cell adhesion molecules such as E-
cadherin and zonula occludens protein ZO-1 are replaced by the (ii) mesenchymal markers -
SMA and the intermediate filament protein vimentin. The loss of cell adhesion is 
accompanied by (iii) cytoskeletal remodelling and morphological changes resulting in tubular 
basement membrane disruption. (iv). Consequently these cells possess the ability to migrate 
from the tubular basement membrane (TBM) into the interstium. This migratory capacity 
leads to increased deposition of the ECM and renders EMT key in the pathology of 
tubulointerstitial fibrosis. Normally, tubular epithelial cells form a highly coupled epithelial 
sheet held together by the adhesion molecule Epithelial (E)-cadherin. Loss of E-cadherin 
expression occurs in the early stages of EMT and results in the dissociation of cells within the 
epithelial sheet [6]. This represents the beginning of a series of events culminating in 
transition from an epithelial-to-mesenchymal phenotype. Changes in E-cadherin are rapidly 
accompanied by an up-regulation of mesenchymal markers. Re-organisation of the actin 
cytoskeleton into stress fibres containing de novo expressed -SMA is accompanied by an 
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exchange of cytokeratin for vimentin filaments and the expression of fibroblast-specific-
protein (FSP1), a Ca
2+
-binding protein involved in motility, invasion, and tubulin 
polymerization. These morphological and phenotypic changes support matrix remodelling and 
the migration across the TBM into the interstitial environment where these cells further 
exacerbate fibrosis [7].  
 
The migratory phenotype, used to define EMT remains controversial, especially in the context 
of fibrosis [8]. Loss of an epithelial phenotype can be clearly identified by a loss in the 
expression of specific epithelial proteins, in particular E-cadherin. Acquisition of a 
mesenchymal phenotype is more difficult to attribute [9] and may explain why EMT is often 
overlooked in studies of renal disease. Markers classically used to define EMT include 
vimentin and -SMA [10]. However, vimentin is not specific for fibroblastoid cells [11], 
whilst -SMA, the most commonly used marker in EMT exhibits heterogeneity of expression 
[12]. Clarification of EMT in fibrosis is dependent on the identification of a complex 
interplay of both phenotypic and morphological changes. 
 
The pathology of EMT:  
A role for EMT in the progression of chronic kidney disease (CKD) was first demonstrated by 
Iwano et al in a model of unilateral ureteral obstruction (UUO) where 36% of the matrix 
producing cells resident within the tubulointerstitial space were found to be of epithelial 
origin and derived from renal tubular epithelium through EMT [13]. The underlying 
pathology of EMT has since been observed in human renal biopsies from diseased kidney, a 
feature confirmed by the presence of myofibroblasts in which the proportion of cells 
undergoing EMT was found to correlate to both the level of serum creatinine and the degree 
of interstitial fibrosis [14][15]. In models of renal disease, EMT occurs in response to 
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hypoxia, reactive oxygen species, advanced glycation end products (AGEs) and numerous 
prof-fibrotic cytokines, growth factors and metalloproteinases [16]. Of these, the pro-fibrotic 
cytokine TGF- is a likely candidate in the development and progression of fibrotic 
complications observed in DN [17]. 
 
EMT and the pathogenesis of fibrosis in DN: 
In diabetes, glomerular fibrosis is observed in the early progression from incipient to overt 
nephropathy [18]. Whilst tubulointerstitial fibrosis can also present itself in these early stages, 
a build up of fibrotic material in the tubular interstitium tends to accompany disease 
progression, correlating with a gradual decline in renal function [19]. Although the origin of 
fibroblasts in DN remains less clear, progressive renal fibrosis may, in part, be mediated by 
the phenotypic changes induced by EMT. Analysis of renal histology in both diabetic animals 
and from the kidneys of patients with DN, confirms the existence of EMT- induced changes. 
Markers of EMT have recently been observed in STZ treated Wistar Kyoto rats, Sprague 
Dawley rats and the STZ Ren-2 rat [20][21]. These studies suggest that EMT is closely 
correlated to a decline in renal function [15]. Recent studies by Yamaguchi et al have 
suggested that the existence of FSP-1 in podocytes from patients with diabetes is most likely 
to be associated with induction of podocyte detatchment through EMT, a potential 
catastrophic event since the depletion of glomerular podocytes is an important feature of 
progressive DN [22]. 
 
A role for TGF-1, Smads and EMT in DN:  
A broad spectrum cytokine, TGF-β regulates many biological processes [23][24]. Of its three 
isoforms (TGF-β1, β2 and β3) TGF-β1 is the principal mediator of diabetic complications and 
is key in the development of hypertophy and the accumulation of ECM [25][26]. In models of 
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renal disease and diabetes, TGF-β1 gene expression and secretion are increased [27][28], an 
up-regulation that is in part, due to, elevated glucose , AGEs, PKC and the MAPK pathway 
[29][30][31][32]. However, despite extensive data demonstrating TGF-β induced fibrosis, the 
underlying events mediating the development of the fibrotic lesion are poorly understood. In 
diabetes, TGF-1 contributes to excessive deposition of fibrotic material through EMT, 
modulating the expression of several epithelial cell recognition and organizational proteins, 
including the cadherins, catenins as well as the actin cytoskeleton [33]. In human mesangial 
cells, TGF-1 induces -SMA, collagen type I expression and cell hypertrophy [34]. 
Furthermore, the downregulation of E-cadherin expression with the concomitant upregulation 
of -SMA in tubular epithelial cells, strongly supports the case for TGF-1 as a potent 
stimulus of EMT [35].  
 
Predominantly mediated via Smad dependent pathways, TGF-β1 binds to a distinct receptor, 
TGF-β receptor II (TβRII), that activates the TGF- receptor type I (TβRI)-kinase. This 
association results in the downstream phosphorylation of the Smad proteins. Smads are 
subdivided into three classes; Receptor regulated (R) Smads (Smad 1, 2,3,5 and 8), the 
Common (Co) Smads (Smad4) and the Inhibitory (I) Smads (Smad6 and 7). Following TβRII 
activation, R-Smads form oligomeric complexes with the common Smad (Co-Smad) prior to 
translocation and regulation of gene transcription [36]. Transfected cells with a mutant TβRI 
fail to exhibit TGF-1 induced EMT in the absence of Smad activation, despite exhibiting full 
kinase activity [37]. The majority of TGF- targeted genes regulated in EMT appear to be 
reliant on Smad3 dependent transcriptional regulation [38], though a role for Smad2 should 
not be discounted [39]. Differential roles for both Smad2 and Smad3 have been identified 
[40], and a Smad3 dependent reduction of E-cadherin in human proximal tubular cells (hPTC) 
is paralleled by a Smad2 dependent induction of metallomatrix proteinase 2 [41]. Microarray 
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analysis of TGF-1-induced EMT in mouse and human epithelial cells demonstrates a critical 
requirement for Smad signalling in the regulation of all tested target genes [42]. Smad 
signalling is stringently controlled in order to protect the cells from an unwanted TGF- 
response, and a safeguard mechanism exits in the form of both inhibitory Smads and 
transcriptional co-repressors [43]. The inhibitory Smads (Smad6 and Smad7) inhibit R-Smad 
phosphorylation by blocking their access to TβRI, and/or by promoting the degradation of the 
receptor complexes. Co-repressors SnoN (Ski-related novel gene, non Alu-containing), Ski 
(Sloan-Kettering Institute proto-oncogene), and TGIF (TG-interacting factor) prevent gene 
transcription through inhibition of R-Smads [43]. These antagonists are critical in ensuring 
the regulation of Smad-mediated gene transcription, therfore a fine balance must be achieved 
in order to match the demands of the cell. It is no surprise, that diminished levels of co-
repressors SnoN, Ski and TGIF are observed in animal models of obstructive nephropathy and 
diabetes [44]. Smad ubiquitination regulatory factor-2 (Smurf2) is an ubiquitin ligase that 
specifically targets certain members of Smad proteins for degradation, including Ski, SnoN 
and TGIF [45]. The close association between Smurf2 expression and enhanced SnoN 
degradation [44] suggests that the dysregulation of Smurf2 is most likely to affect profibrotic 
TGF-β/Smad signalling and may contribute to the development and progression of human 
kidney fibrotic diseases [45].  
 
TGF- SGK1 and EMT in the collecting duct:  
The role of TGF- in more distal regions of the nephron is yet to be established. In the 
collecting duct, TGF- promotes increased expression of the serum and glucocorticoid 
inducible kinase-1 (SGK1), a serine/threonine kinase that regulates sodium re-absorption 
through control of the epithelial sodium channel (ENaC) [46]. SGK1 is elevated in models of 
diabetes [47], suggesting that it may contribute to the development of secondary hypertension. 
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Interestingly SGK1 is expressed in numerous tissues that exhibit fibrosis including cases of 
Crohn's disease, lung fibrosis, liver cirrhosis, fibrosing pancreatitis, DN and 
glomerulonephritis [48]. These studies suggest that SGK1 may mediate some TGF--induced 
fibrotic effects. In diabetic mice SGK1 potentiates the effect of high glucose on fibronectin 
formation [49], a response that in human fibroblasts has been found to be dependent on the 
epidermal growth factor receptor (EGFR) [50]. EMT has been confirmed in the collecting 
duct in a model of fetal UUO [51] and both insulin growth factor 1 (IGF1) and TGF-1 have 
been shown to induce classic EMT-like changes in mouse inner medullary collecting duct 
cells [52], despite initial studies suggesting that these cells could not undergo phenotypic 
conversion in response to TGF-1 [53]. How TGF-1 induced EMT contributes to fibrosis in 
the distal nephron is unclear. In 2009 Aldehni F et al. demonstrated that TGF- induced 
EMT in mouse renal collecting duct increased levels of Bestrophin 1 (Best1), a compound 
which controls intracellular Ca
2+
 concentration and increases cellular proliferation [54]. 
Suppression of Best1 by RNAi inhibited proliferation and down-regulated markers of EMT, 
suggesting that Best1 may function as a downstream mediator of TGF-1 induced EMT and 
renal fibrosis in the CD.  
 
Therapeutic intervention:  
Although TGF-1 is regarded as the major isoform involved in fibrosis, improved renal 
function coincides with reduced expression of both TGF-1 and 2 [55]. Furthermore, a pro-
fibrotic role for all 3 isoforms has been observed in diabetes [56]. The pro-fibrotic actions of 
TGF- make it an ideal therapeutic target for reno-protective agents. Neutralizing TGF-1, 
TGF-2 or TGF-3 reduces renal scarring and diminishes a loss of kidney function [57][58]. 
Inhibition of TGF- in this way also prevents glomerular enlargement and suppresses the 
expression of genes encoding for the ECM in models of chemically induced diabetes [57]. 
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These findings were corroborated in db/db mice, where both TGF- and TGF- receptor 
mRNA expression were increased [58]. Chronic treatment of these animals with TGF-β-
neutralizing antibodies markedly diminished the expression of collagen and fibronectin and 
reduced mesangial matrix expansion. Several anti-fibrotic and reno-protective agents have 
been shown to partially alleviate TGF- induced fibrosis and include, Bone Morphogenic 
Protein 7 (BMP-7) and Hepatocyte Growth Factor (HGF). 
 
Identified as an osteogenic factor, BMP-7 plays an important role in kidney development and 
the regulation of nephrogenesis associated with MET. Renal fibrosis in diabetes is inhibited 
by BMP-7. Following EMT, increased levels of TGF- are paralleled by a reduction in 
expression of BMP-7, as a potential consequence of increased gremlin levels [59]. Gremlin 
limits BMP-7 availability and is markedly elevated in humans with DN [60]. This reciprocal 
relationship accounts for low BMP-7 concentrations in models of acute and chronic renal 
injury [61], and explains how exogenous BMP-7 restores renal function through blockade of 
EMT [62]. Aside from the glomerular reno-protective effects observed in both STZ rats and 
db/db mice, BMP-7 is capable of intercepting at the level of TGF- signalling. In the adult, 
BMP-7 alleviates TGF-β-induced renal fibrosis [63] and antagonises TGF--induced Smad3-
dependent EMT [64]. However, the mechanism remains elusive since BMP-7 is unable to 
negate TGF- induced EMT in human PTC, suggesting that the effects of BMP-7 are region 
specific [65]. The extent by which BMP-7 blocks EMT requires further clarification. 
 
A key anti-fibrotic cytokine, HGF prevents renal tissue fibrosis after chronic injury [66]. 
Administration of HGF reduces loss of kidney function, whilst blockade of HGF signalling 
further exacerbates the extent and progression of renal fibrosis [67]. As with BMP-7, HGF 
and TGF- have a reciprocal relationship. HGF inhibits TGF- induced EMT, and 
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ameliorates renal fibrotic lesions in numerous renal disease models [67]. The underlying 
molecular mechanisms mediating these reno-protective effects are unknown. The anti-fibrotic 
activity of HGF appears to stem from up-regulation of the transcriptional co-repressor SnoN. 
Binding of this co-repressor to Smad-2 results in formation of a transcriptionally inactive 
complex, preventing the activation of Smad mediated genes thereby blocking TGF- induced 
EMT [68]. Administration of HGF has been shown to alleviate renal complications in DN, 
including the reversal of glomerulosclerosis [69], a reduction in albuminuria [70] and 
blockade of fibrosis with a concomitant improvement in renal function [71]. However, a 
number of studies contradict these findings, suggesting that chronically elevated HGF 
promotes the progression of nephropathy in db/db mice [72]. Furthermore, potential proto-
oncogenic actions of HGF raises questions as to the potential therapeutic use of this growth 
factor in alleviating EMT induced complications in DN. Further studies are essential if HGF 
is to be considered as a future therapeutic intervention for fibrosis in DN. 
 
EMT is a complex process involving numerous downstream signalling cascades. Strategies to 
disrupt any one of these may negate EMT and prevent fibrosis. Identifying other reno-
protective agents may unearth future therapeutic interventions. Potential candidates recently 
identified upstream of HGF include, 9-cis retinoic acid, 1,25-dihyrdoxyvitamin D3, the 
PPAR agonist troglitazone and C-peptide [33][69][70][71]. A cleavage product of pro-
insulin, C-peptide exerts a number of protective affects against the micro-vascular and macro-
vascular complications associated with hyperglycaemia [72] and in patients with DN, C-
peptide is reno-protective [73]. Furthermore, C-peptide has been shown to negate TGF- 
induced EMT in cells of the proximal tubule [33]. As an adjunct to insulin therapy, C-peptide 
could be used to alleviate some renal complications of diabetes. However, like BMP-7 and 
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HGF these findings are preliminary and whilst encouraging, need to be fully corroborated in 
the clinical scenario. 
 
Conclusion:  
TGF- induced EMT is a key contributor to fibrotic scar formation as seen in DN. 
Manipulating downstream TGF- signalling represents a viable therapeutic target to alleviate 
fibrosis and restore renal function. Administration of the anti-fibrotic growth factors HGF or 
BMP-7 can reverse the fibrogenic response and growing evidence supports the use of novel 
reno-protective agents to assist in alleviating complications of CKD, including DN. 
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